Tamoxifen is an antiestrogen with proven efficacy and low toxicity in the treatment of breast cancer. However, tamoxifen has been shown to exert a number of nonhormonal as well as hormonal effects. One nonhormonal effect of tamoxifen is the induction of transforming growth factor-p (TGF-p) secretion. TGF-P has been implicated in the pathogenesis of radiation-induced fibrosis. Purpose: We investigated the development of lung fibrosis in breast cancer patients who were treated after mastectomy with radiotherapy, with or without simultaneous adjuvant treatment with tamoxifen. Methods: Data from 196 women were included in the analysis. Eighty-four women were postmenopausal patients who participated in a randomized trial testing tamoxifen as an adjuvant to postmastectomy radiotherapy. The radiotherapy technique employed an 8-MV photon field covering the axillary and the infraclavicular and supraclavicular regions of the affected side of the chest; the chest wall was treated with an abutted electron field. Optical density changes in pretreatment and post-treatment chest x-ray Films were used to monitor the development of lung fibrosis; lung reactions were assessed in the photonirradiated field only. Logistic regression analysis was used to explore relationships between radiation dose and the development of lung fibrosis in
Background:
Tamoxifen is an antiestrogen with proven efficacy and low toxicity in the treatment of breast cancer. However, tamoxifen has been shown to exert a number of nonhormonal as well as hormonal effects. One nonhormonal effect of tamoxifen is the induction of transforming growth factor-p (TGF-p) secretion. TGF-P has been implicated in the pathogenesis of radiation-induced fibrosis. Purpose: We investigated the development of lung fibrosis in breast cancer patients who were treated after mastectomy with radiotherapy, with or without simultaneous adjuvant treatment with tamoxifen. Methods: Data from 196 women were included in the analysis. Eighty-four women were postmenopausal patients who participated in a randomized trial testing tamoxifen as an adjuvant to postmastectomy radiotherapy. The radiotherapy technique employed an 8-MV photon field covering the axillary and the infraclavicular and supraclavicular regions of the affected side of the chest; the chest wall was treated with an abutted electron field. Optical density changes in pretreatment and post-treatment chest x-ray Films were used to monitor the development of lung fibrosis; lung reactions were assessed in the photonirradiated field only. Logistic regression analysis was used to explore relationships between radiation dose and the development of lung fibrosis in patients either receiving or not receiving tamoxifen. All P values are from two-sided tests. Results: Among the 84 women who participated in the randomized trial of radiotherapy plus tamoxifen (n = 38) versus radiotherapy alone (n = 46), there was a significant association between tamoxifen treatment and the incidence of marked lung fibrosis (relative risk = 2.0; 95% confidence interval [CI] = 1.2-3.5; P = .01). When logistic regression analysis was used to evaluate data from all 196 patients, a highly significant relationship was found between the incidence of lung fibrosis and total radiation dose (P = .0005). In the full analysis, an increased risk of marked lung fibrosis was found again for patients who received tamoxifen simultaneously with radiotherapy (with patients receiving radiotherapy alone as the referent, odds ratio = 2.9; 95% CI = 1.3-63; P = .007). Patient age and menopausal status did not significantly influence the results. Conclusion: Tamoxifen treatment during postmastectomy radiotherapy enhances the risk of radiation-induced lung fibrosis. Implications: In view of pre-existing data, we hypothesize that tamoxifen mediates the enhancement of radiation-induced lung fibrosis through the induction of TGF-P secretion. If this hypothesis is correct, new strategies might be devised for preventing or reducing radiation-induced fibrosis. Because we studied a relatively small portion of the irradiated lung, we cannot recommend changes in current therapeutic measures; however, we strongly encourage additional studies of lung fibrosis in patients receiving tamoxifen and radiotherapy. [J Natl Cancer Inst 1996;88:918-22]
Tamoxifen is a drug with proven efficacy and low toxicity in the treatment of early breast cancer (J). The mechanism of action of this compound is not completely understood, but it has been shown to exert a number of hormonal as well as nonhormonal effects. One of the documented nonhormonal effects of tamoxifen is the induction of cellular secretion of the multifunctional cytokine transforming growth factor-P (TGF-p) (2) . In a clinical study, Butta et al. (J) found that 3 months of tamoxifen treatment led to increased levels of extracellular TGF-P around the stromal fibroblasts in breast cancer biopsy specimens (compared with the levels found in pretreatment specimens from the same individuals).
TGF-P has a number of biological effects, including the regulation of other growth factors. At the cellular level, its effect depends on the identity of the target cell; for example, it generally inhibits the growth of epithelial cells, but it causes chemotaxis of fibroblasts (4, 5) . The first property (growth inhibition) has been proposed as a possible mode of action of tamoxifen in estrogen receptornegative tumor cells (6) , whereas the second property (stimulation of chemotaxis) may explain the importance of TGF-P in the pathogenesis of fibrosis in a large number of animal models and human disorders (7) . In medical conditions characterized by the formation of pulmonary fibrosis, a number of studies have shown that TGF-P is involved. Phan and Kunkel (8) showed that TGF-P messenger RNA (mRNA) was present in mice expressing lung injury after treatment with bleomycin, but it was not found in nonresponding animals. They showed further that the increase in TGF-p mRNA preceded an increase in the mRNAs for collagen types I and III. In addition, increased TGF-P levels have been observed in coal miners who developed lung fibrosis (9) and in individuals with certain disorders causing the formation of pulmonary fibrosis, such as sarcoidosis (70) and autoimmune diseases with lung involvement (7/) .
Considering the effects of radiation, experimental evidence is accumulating in favor of an association between TGF-P and radiation-induced fibrosis in the liver (12,13), skin and muscle (14) , intestine (75) , and mammary gland (76) . Finkelstein et al. (77) found a dose-dependent increase in the level of TGF-P mRNA in mice after thoracic irradiation. This increased expression was seen at both assay times used, 1 and 14 days, after irradiation. However, no attempt was made to correlate TGF-P mRNA levels directly with the formation of lung fibrosis.
Our goal in this clinical study was to determine whether concomitant administration of tamoxifen increased the risk of developing lung fibrosis after postmastectomy radiotherapy. Two analyses were done. The first analysis was based on patients participating in a randomized trial evaluating tamoxifen as an adjuvant to surgery and postoperative radiotherapy. The second analysis was of a more radiobiologic orientation and was aimed at elucidating how tamoxifen treatment affected the radiation dose-response relationship for lung fibrosis. To this end, a group of nonrandomized concurrent control subjects, treated with radiotherapy alone, was added to increase the statistical power and the variability in prescribed radiation doses.
Subjects and Methods
The patients described in this report are a subset of the 229 women included in the Aarhus (Denmark) study of normal-tissue effects of postmastectomy radiotherapy. The Aarhus study population was accrued from 1978 through 1982. Details of patient treatment, dosimetry, and clinical follow-up have been reported previously (18) (19) (20) . Only the most relevant features of the patient population and its treatment are presented here; details of the radiotherapy technique and the dose-fractionation schedules are also summarized below.
Patient Follow-up and Tamoxifen Treatment
Patients were followed regularly for a minimum of 5 years or until the time of death. Planned followup visits were scheduled at intervals of 6 months for the first 1-2 years and at yearly intervals thereafter. Additional follow-up visits were scheduled on the initiative of the patient and/or her general practitioner, if indicated. At each visit, a routine chest x ray was taken to screen for pulmonary metastases. These chest x rays formed the basis for the quantitative assessment of late radiologic lung changes using the assay described below. To qualify for evaluation with this assay, at least one pretreatment x ray and one x ray taken more than 12 months after radiotherapy had to be available. Also, a patient's anterior-posterior (AP) diameter had to be recorded in the medical records to facilitate estimations of the radiation dose at the level of the mid-axilla. Of the 229 patients, 197 met these criteria. None of the patients had been treated with chemotherapy.
Tamoxifen was tested as an adjuvant to surgery and postmastectomy radiotherapy in postmenopausal women in the randomized DBCG 77 C trial conducted by the Danish Breast Cancer Collaborative Group (DBCG) (2/). Of the 197 patients described above, 84 were included in the DBCG 77 C study (Table 1) . Radiotherapy was started 2-4 weeks after surgery, and tamoxifen treatment was initiated simultaneously. Tamoxifen was administered orally at a dose of 3 x 10 mg daily for 48 weeks.
To establish radiation dose-response curves and to look at other possible predisposing factors for lung injury, such as menopausal status and patient age, the whole series of patients was analyzed as well. The 113 patients who were not in the DBCG 77 C trial were treated concurrently in the Department of Oncology in Aarhus using exactly the same radiotherapy technique. One of these patients received adjuvant tamoxifen outside of the DBCG 77 C trial and was excluded from the analysis. Thus, a total of 196 patients were included in this study.
Radiotherapy Technique, Dosimetry, and Fractionation
All patients were treated with an anterior 8-MV photon field covering the axillary and the infraclavicular and supraclavicular areas of the affected side of the chest. The same linear accelerator was used in all cases. Individually shaped shielding blocks, positioned by means of skin marks drawn during fluoroscopy, protected the humerus from the level of the caput humeri, the larynx, and the lung below the level of the second rib. The chest wall •Numbers in parentheses = percentages of total in each treatment subgroup. tParticipants in DBCG 77C trial (21) . JOf these 91 patients, 73 had the dose prescribed as a maximum absorbed regional dose (51.4 Gy) rather than as a minimum target dose (36.6 Gy) at the level of the mid-axilla.
§,IIWilcoxon rank sum tests comparing the distributions of age and anterior-posterior diameter in the RT + tamoxifen versus RT-alone groups of randomly assigned postmenopausal patients: §/* = .83; \\P = .43.
was treated with an abutted electron field. In this report, lung reactions were assessed in the photonirradiated apex of the lung only.
Although the treatment technique remained essentially unchanged from 1978 through 1982, two different dose-fractionation schedules were used for this series of patients (Table 1) . From 1978 through 1980, radiation was delivered in 12 dose fractions, following DBCG guidelines. This radiotherapy was prescribed with a minimum target dose, specified at the level of the mid-axilla, of 36.6 Gy. The radiation was delivered over a period of 37-46 days. All patients included in the DBCG trials received radiation treatment prescribed this way. However, patients not included in clinical trials often had radiotherapy prescribed as a maximum absorbed regional dose of 51.4 Gy instead. Beginning in 1981, the number of treatment fractions was increased to 22, and the dose was increased according to the nominal standard dose formula {18). After this change was instituted, all patients were treated with the practice of dose prescription at the level of the mid-axilla. The minimum target dose was 40.9 Gy, given in 22 fractions during a period of 29-35 days.
The dosimetric reference point for lung fibrosis was chosen on the central axis of the photon beam at the level of the mid-axilla. The exact procedure for identifying the mid-axilla and the associated AP diameter of the patient has been described elsewhere (18) .
Lung Density Assay
An assay of lung density changes based on chest x-ray films has been developed and described recently (22) . In brief, this assay quantifies changes in optical density along two standardized reference lines, which were established using bony landmarks that can be easily identified on the films. Radiologic lung changes are quantified in terms of the Relative Equivalent Absorber Thickness (REAT). The optical density of an x-ray film is converted into an equivalent absorber thickness, and the ultimate change in this quantity as a percentage of the pretreatment value is defined as the REAT. This assay has been validated (22) by demonstrating a highly significant correlation between the REAT and late lung changes scored in a blinded manner according to an arbitrary 4-point scale by a team of two experienced physicians (an oncologist and a radiologist). The reproducibility of this type of assessment was determined by evaluating 43 pairs of clinical chest x rays, each representing two films of the same patient exposed during the same examination. These x-ray films were treated as double determinations of the REAT, and the standard deviation for this series was found to be 1.35%.
For the purpose of this analysis, a dichotomous response variable was defined as follows. The ultimate REAT was estimated as the average value of all REAT measurements obtained more than 1 year after the end of radiotherapy. The average number of such values per patient was 4.75 (range, 1-20). A responder was a patient with marked lung fibrosis defined by an ultimate REAT exceeding 69b. This threshold was chosen somewhat arbitrarily, but it was influenced by two concerns. First, in view of the 1.35% standard deviation estimated from the double exposures described above, a 6% difference in REAT would be significantly different from 0, even in patients with only one follow-up x ray. Second, this level ensured reasonable resolution on the incidence scale throughout the range of dose fractionation applied in the present study.
Statistical Analysis
Data from the 84 postmenopausal patients who were randomly assigned either to receive or not to receive tamoxifen were analyzed using the FREQ procedure in the SAS statistical software package (release 6.08; SAS Institute Inc., Cary, NC). This analysis was conducted to evaluate a possible association between radiation-induced lung fibrosis and tamoxifen treatment after controlling for the number of radiation fractions received. The statistical significance of the identified association was assessed by use of the Cochran-Mantel-Haenszel test, and its strength was characterized by use of the common relative risk estimate.
Logistic regression modeling was performed using the LR program contained in the BMDP statistical software package (Dynamic version 7.0; Biomedical Data Package Statistical Software, Inc., Los Angeles, CA). The effect of radiation-dose fractionation was represented by a linear-quadratic dose-effect relationship, i.e., by including terms in the model proportional to dose and to dose times dose per fraction (23) . Thus, for a patient with a total absorbed dose at the level of the mid-axilla, D, treated in N fractions, the probability (p) of developing lung fibrosis was assumed to be of the form:
where D 1 -Here, exp is an exponential function with the base e, and OQ, a h .. . are the regression coefficients to be estimated from a logistic regression analysis of the data. /" is a so-called indicator or '0-1' variable set equal to 1 if the patient was randomly assigned to receive tamoxifen and set equal to 0 otherwise. In addition to tamoxifen treatment and radiation dose fractionation, the possible effects of two other clinical characteristics were tested in the model. Menopausal status was represented in a manner similar to tamoxifen treatment. Age was represented in alternative ways, i.e., either as a continuous variable (namely, the actual age in years) or as an indicator variable set equal to 1 if the patient's age was above the median value (63 years) or equal to 0 if the patient's age was below the median value. All reported P values are from two-sided tests.
Results
The absorbed radiation dose in the lung for this patient population was heterogeneous. However, no significant differences were found in the distributions of patient AP diameters among the three groups analyzed (Wilcoxon rank sum test; P>.26 for any two groups).
Among the 84 randomly assigned patients, tamoxifen was found to increase the risk of lung fibrosis significantly ( Table 2 ). The common relative risk estimate, after adjusting for dose-fractionation group, was 2.0 (95% confidence interval [CI] = 1.2-3.5). This risk estimate was significantly different from 1.0 (P -.01). There was no indication of a lack of homogeneity in the odds ratios (BreslowDay test; P = .89), meaning that there was no statistically significant dependence of the relative risk on the number of radiation fractions received. Fig. 1 shows the dose-response relationships for lung fibrosis when the entire 196-patient population was considered. Logistic regression analysis of the data showed a highly significant relationship between the radiation dose squared and the probability of developing lung fibrosis (P = .0005). The only other clinical characteristic having a significant effect on the risk of fibrosis was treatment with tamoxifen (likelihood ratio test; P = .007); the odds ratio was estimated to be 2.9 (95% CI = 1.3-6.3). An alternative method for specifying the effect of tamoxifen on the radiation dose-response curve is to estimate the radiation dose required for a 50% incidence of lung fibrosis, the RD^, when treating in 22 fractions. For patients receiving radiotherapy alone, the RD 50 was 55.4 Gy; for patients receiving radiotherapy plus tamoxifen, the RD^ was 45.6 Gy. Menopausal status did not influence the results significantly (P = .61), and the influence of patient age was not statistically significant at the 5% level either when entered as a continuous variable or when dichotomized (below and above the median age of 63 years). However, in the latter case, the P value was .06, and this parameter (age as a dichotomized variable) was included in the modeling to see if it changed the effect of tamoxifen on the risk of lung fibrosis. It did not. The tamoxifen effect was still significant (P = .011), with an unchanged estimate of the odds ratio = 2.9 (95% CI = 1.3-6.3).
Discussion
To our knowledge, this study is the first of its kind to look for a clinical association between tamoxifen treatment and radiation-induced lung fibrosis. Two other studies (2425) have considered the possible influence of tamoxifen on the •Refers to the number of fractions into which the total radiation dose was divided/delivered. tCochran-Mantel-Haenszel test for association between lung fibrosis and adjuvant tamoxifen stratified for number of fractions; P = .01.
cosmetic outcome of lumpectomy followed by postoperative radiotherapy. Wazer et al. (24) found a borderline significant (P = .06) increase in the risk of having a poor cosmetic outcome in patients who received tamoxifen. Fowble et al. (25) found no major effect of tamoxifen on cosmetic outcome, except when the breast and regional lymph nodes were irradiated. In such cases, 86% of the patients receiving tamoxifen had a "good to excellent" cosmetic outcome in comparison with 92% of the patients not receiving tamoxifen. Also, breast edema was more common in patients receiving tamoxifen (49% versus 31%). Although cosmetic outcome after this type of treatment is likely to be influenced by subcutaneous and muscular fibrosis, there are a number of other risk factors related to the surgical procedures and other patient characteristics.
It is not clear from our study whether the predominant effect of tamoxifen is on the induction of radiation injury or whether it is through a postirradiatory modification of the processing of radiation injury in the tissue. Therefore, it remains to be determined whether any benefit would accrue from withholding tamoxifen treatment until radiotherapy is completed. The case report by Parry (26) , concerning a patient who experienced radiation recall of skin reactions induced by tamoxifen, suggests that interactions may occur, even when the two treatment modalities are separated in time. However, the biologic mechanism behind this observation is not known.
The group of premenopausal patients in our study population, comparable in number to the group of patients treated with tamoxifen, did not experience a risk of lung fibrosis that was different from that of other patients, making it unlikely that tamoxifen exerts its effect on lung fibrosis through a hormonal or antihormonal mechanism. The fact that the effect of tamoxifen on lung fibrosis was significant among the randomly assigned patients, where treatment techniques and dose prescriptions were strictly identical, minimizes the possibility of selection bias. Furthermore, lung fibrosis was evaluated by means of an objective assay. These two circumstances add to the credibility of the present findings. To further elucidate the effect of tamoxifen, a radiation doseresponse analysis was conducted using multivariate logistic regression. This analysis confirmed the strong doseresponse relationship for lung fibrosis evaluated by the film densitometry assay and showed how tamoxifen shifted the position of the dose-response curve.
From a clinical perspective, it would seem premature to take any drastic therapeutic measures, such as lowering the radiotherapy dose in patients receiving tamoxifen. One reason is that patients with apical lung fibrosis are frequently without pulmonary symptoms. This lack of symptoms may be explained by the relatively small portion of the total lung volume affected. When lung-damage scores from the part of the lung exposed to the electron field are taken into consideration, a significant correlation exists between radiologic lung changes and patient symptoms (27) . However, radiation reactions in this part of the lung were not assessed in the current study because of the difficulty in accurately establishing the absorbed dose to the lung from the electron beam. Therefore, we strongly encourage that the enhancement of radiation-induced fibrosis be considered in other series of patients receiving radiotherapy with or without simultaneous treatment with tamoxifen.
In view of our findings and results described in the literature, we hypothesize that tamoxifen enhances radiation-induced lung fibrosis through an increase in TGF-P secretion. As described above, there is substantial evidence supporting an important role for TGF-P in the development of pulmonary fibrosis. A clinical study (28) in patients undergoing autologous bone marrow transplantation (ABMT) for advanced breast cancer showed that the plasma concentration of TGF-P after induction chemotherapy but before high-dose chemotherapy and ABMT was associated with a risk of veno-occlusive disease and radiation-induced lung reactions. However, the lung reactions were indicated by clinical symptoms beginning 40-75 days after ABMT. No biopsy specimens were obtained. Anscher et al. (29) have suggested that fibrosis formation is mediated not only by TGF-fi produced locally in the irradiated normal tissue but also by circulating TGF-P released by tumor cells. Although circulating TGF-P might have had a role in the present findings, it appears unlikely that this TGF-p was released by primary tumor cells, since all of the patients in our study underwent mastectomy and had no macroscopic disease at the time of radiotherapy. Animal studies are currently in progress in our laboratory to elucidate further the possible interaction between tamoxifen and radiation.
One interesting question arising from this study is whether pulmonary fibrosis might be prevented, or at least reduced, by intervention in the pathogenic pathway. Preliminary results have shown that TGF-P antagonists may inhibit or reduce the action of this growth factor in the kidney (30) and skin (31) as well as in the case of bleomycin-induced lung fibrosis (32) . If similar strategies could be developed from an improved understanding of the radiation-induced pathogenesis of lung fibrosis, an improved therapeutic outcome might be achieved for several human cancers, either via a reduction in the level of late radiotherapy sequelae or by improving tumor control by escalating the radiation dose.
